B of A Securities Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $149
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $139 to $149.
B of A Securities analyst Tazeen Ahmad maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $139 to $149.